Deborah Rathjen, Executive Chair of Bioasis Technologies Inc. (TSXV: BTI | OTCQB: BIOAF), highlights the company’s xB3 platform which is being developed to treat patients who suffer from a variety of central nervous system disorders.
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
» Subscribe to Market One: http://bit.ly/2CYmf2y
Learn more about Bioasis Technologies on their website: https://www.bioasis.us
See how your company can reach millions of investors on BNN Bloomberg through the Market One Minute: https://bit.ly/2JcqR8X
Engage with Market One
» Like us on Facebook: https://www.facebook.com/marketonemediagroup/
» Follow us on Twitter: https://twitter.com/MarketOneMedia
» Connect with us on LinkedIn: https://www.linkedin.com/company/market-one-media-group-inc-
» Follow us on Instagram: https://www.instagram.com/marketonemediagroup/
0 Comments